Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM ESTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.
The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More
Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage
February 3, 2022 10:37 AM ESTShares of Biogen (NASDAQ: BIIB) are down 3% in todays trading session after the company reported mixed results and guidance.
The biotechnology company reported EPS of $2.50, or $368.2 million, up from $2.33 per share, or $357.9 million, from the year-ago quarter. Adjusted EPS came in at $3.39, beating the FactSet consensus of $3.37.... More
